Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 21, 2014
Pharmacy Choice - News - Pharmaceutical Development - October 21, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/21/14 - Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the initiation of a Phase 1/ 2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma that carry an isocitrate dehydrogenase-2 mutation.
10/21/14 - AnthroTronix Secures FDA Clearance for Brain Health Assessment Tool [Health & Beauty Close - Up]
"We are pleased that DANA has sought and received FDA clearance, leading the way for this type of game-changing technology," said Corinna Lathan, founder and CEO of AnthroTronix. "With the steady growth of the mHealth movement, technology that has evidence and science-based functionality is critical," said Duke University Medical Center's Murali D
10/21/14 - BioSpecifics Tech. Reports FDA Approval Of SBLA For XIAFLEX
WASHINGTON- The U.S. Food and Drug Administration or FDA has approved the supplemental Biologics License Application or sBLA submitted by BioSpecifics Technologies Corp.' s partner, Auxilium Pharmaceuticals Inc., for XIAFLEX for the treatment of up to two Dupuytren's contracture cords in the same hand during a single treatment visit.
10/21/14 - BioSpecifics Technologies Corp. Announces FDA Approval of sBLA for XIAFLEX for the Concurrent Treatment of Two Dupuytren's Contracture Cords
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in the EU, today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application submitted by BioSpecifics' partner, Auxilium...
10/21/14 - Boehringer Ingelheim initiates global Phase III study investigating nintedanib in patients with colorectal cancer
Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal cancer. "Based on previous clinical studies with nintedanib, BI will initiate the LUME-COLON 1 study to evaluate this compound as a potential treatment option for patients with refractory colorectal cancer,"
10/21/14 - Cannabis Technologies Inc. Now Trading as InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is pleased to announce the completion of its name change and effective immediately will no longer be trading as Cannabis Technologies Inc. InMed has commenced trading under the stock symbols and. Craig Schneider, President and CEO states, "We are pleased to have completed this milestone of moving InMed into Life Science Sector
10/21/14 - Cell Line Development Market Worth $3.96 Billion by 2019
In 2014, the bioproduction segment accounted for the largest share of the cell line development application market, as cell lines are extensively used in diagnostics, vaccine production, and manufacturing of recombinant protein therapeutics.Dallas, TX 10/21/2014 According to the new market research report The Cell Line Development Market b
10/21/14 - ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study
ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced Phase I data with CCX507, a next-generation potent and specific inhibitor of the chemokine receptor known as CCR9. Data were presented at the ACG meeting being held October 17-22 in Philadelphia.
10/21/14 - Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for the Treatment of Hodgkin's or T-Cell Non-Hodgkin's Lymphoma
There are projected to be approximately 70,000 new cases of NHL, with close to 19,000 deaths, and over 9,000 new cases of HL, with approximately 1,200 deaths, in the United States during 2014.. The single site study, sponsored by Wake Forest Baptist Medical Center and in collaboration with the National Cancer Institute, is a Phase I, open label, do
10/21/14 - Cot Orphan Launches Mobile Application That Transforms Information Access To FDA and EMA Orphan Drug Status
Cot Orphan, LLC, the leader in orphan drug regulatory affairs, today announced the launch of OrphanDB, its first mobile app designed to provide industry leaders a single source of truth to all FDA and EMA orphan drug status through a simple search. Features include:? Granular search for orphan drugs matching criteria such as disease, active com
10/21/14 - CytRx Announces Publication of Phase 1b/2 Aldoxorubicin; NewLink Genetics Announces Licensing Agreement For Development Of NLG919
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 20, 2014.{ nfg} CytRx Corporation, announced that a paper, titled "A Phase 1 b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer So
10/21/14 - DGAP-News: ERYTECH announces granting of new patent in the United States
DGAP-News: ERYTECH PHARMA SA/ Key word: Patent ERYTECH announces granting of new patent in the United States 21.10. 2014/ 10:00- ERYTECH reports positive top-line Phase III results from clinical study with GRASPA (R) in Acute Lymphoblastic Leukemia- GRASPA (R) meets primary endpoin
10/21/14 - Dignitana AB in meeting with the Food and Drug Administration (FDA)
Dignitana AB, a world leader in medical scalp-cooling technology for reducing hair loss related to chemotherapy, is pleased to announce that it has had a formal meeting with the Food and Drug Administration (FDA) in Washington D.C. The intention was to clarify a number of queries regarding the final clinical module. The meeting was held in a positi
10/21/14 - FDA Accepts Lilly's NDA Filing For Empagliflozin/metformin Combination
INDIANAPOLIS- Eli Lilly and Co. Tuesday said the U.S. Food and Drug Administration or FDA has accepted its filing of New Drug Application or NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, which is an investigational compound being studied for the treatment of adults with type 2 diabetes or T2D.
10/21/14 - GenSpera Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients
By a News Reporter-Staff News Editor at Cancer Weekly GenSpera, Inc., a leader in developing prodrug therapeutics for the treatment of cancer, announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer. "We are grateful to the trial investigators for their efforts, as well as the p
10/21/14 - Global Potential Analysis of Ebola Drug and Vaccines Market 2014-2020: Leading Companies are Tekmira, BioCryst, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical
Dublin- Research and Markets has announced the addition of the "Global Potential Analysis of Ebola drug and Vaccines Market through 2020" report to their offering. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activitie
10/21/14 - GVK BIO Announces Successful Completion of Drug Repurposing Efforts to Identify Novel Indications
GVK Biosciences, Asia s leading integrated Discovery Research and Development organization, today announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO s proprietary Drug Repurposing Platform. Nandu Gattu, Vice President- Drug Repurposing at
10/21/14 - Hatchtech Announces Successful Results from Phase 2 Ovicidal Study
Specialty pharmaceutical company Hatchtech Pty Ltd today announced positive results from a Phase 2 clinical study evaluating the ovicidal efficacy of a single, 10 minute application of Xeglyze? Lotion developed as a treatment for head lice infestation. The study met its primary endpoint with Xeglyze? Lotion demonstrating 100% ovicidal efficacy
10/21/14 - IMBRUVICA (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia
Release date- 20102014- RARITAN, NJ- Janssen Research& Development, LLC today announced the submission of a supplemental New Drug Application for IMBRUVICA to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.. IMBRUVICA received FDA Breakthrough Therapy Designation in February 2013 for patients with WM and is being
10/21/14 - Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (EVD) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Monrovia, California- Immunotech Laboratories, Inc. and wholly-owned subsidiary Immunotech Laboratories, BG today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd., located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials
10/21/14 - Infinity Updates on Topline Data from Phase 2a Exploratory Study of Duvelisib in Patients [Health & Beauty Close - Up]
Infinity Pharmaceuticals reported topline data from its Phase 2 a exploratory study of duvelisib, its oral inhibitor of phosphoinositide-3-kinase- delta and PI3K-gamma, in patients with mild, allergic asthma. In this exploratory study, duvelisib showed evidence of activity across several important clinical measures, including improvement in the...
10/21/14 - InVivo Therapeutics Announces Barnes-Jewish Hospital at Washington University as New Clinical Trial Site for Neuro-Spinal Scaffold [Global Data Point]
Dr. Santiago said, "We look forward to participating in the evaluation of this novel treatment for acute spinal cord injury and hope that it we will be able to advance the treatment of patients with spinal cord injuries." With Dr. Santiago and the Barnes-Jewish Hospital, we now have four sites that will be ready to enroll patients once we re-open e
10/21/14 - Iroko Pharmaceuticals Signs New Strategic Agreement With Landsteiner Scientific to Bring ZORVOLEX to Mexico
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX capsules in Mexico. This additional
10/21/14 - Ivantis Announces HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial at Two Years
Ivantis, Inc., developer of the novel Hydrus? Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today announced that the international HYDRUS II trial met its primary endpoint by a wide margin. The data were presented by Thomas W. Samuelson, MD in a paper presentation at AAO 2014, the annua
10/21/14 - J&J -IMBRUVICA (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia
Release date- 20102014- RARITAN, NJ,- Janssen Research& Development, LLC today announced the submission of a supplemental New Drug Application for IMBRUVICA to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc.. IMBRUVICA received FDA Breakthrough Therapy Designation in February 2013 for patients with WM and is being
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415